LIH’s Department of Population Health is currently conducting the second wave of the ORISCAV-LUX study (Observation des Risques et de la Santé Cardiovasculaire au Luxembourg). This study aims to assess the cardiovascular health of Luxembourg’s resident population and to identify the potentially modifiable risk factors to suggest efficient preventive health measures.
On 17th August 2017, the 1000th and 1001st participant, Elizabeth (34) and Gustavo (39), a Spanish couple living in Itzig, had their appointment for the study at LIH and received a special welcome by the ORISCAV-LUX team. Following the appointment, the two participants readily accepted to talk about their motivation to take part in the study and their impressions in an interview with LIH’s Communication Unit.
E: We have a friend working at LIH who participated in the study and suggested us to take part as well.
E: We wanted to know about our current health status. We heard that the participants get a health check, with a feedback on the results of the tests.
G: I specifically wanted to know if everything is fine with my heart, as my father had heart problems. According to the tests that were conducted here, everything is okay. Of course our motivation is also to help research.
E: The research nurses were very nice. We felt comfortable and everything was well explained and easy to understand.
G: Like that, we were not surprised about what happened next during the tests and examinations.
G: This is a difficult question. I have the impression that young people are generally in a good shape, but among the older ones you see more obese people.
E: I try to do a minimum of exercise every week by walking and running. Maybe I do a bit less than the average. And I pay attention to what I eat.
G: Well, we try but we are not always compliant (laughing).
E: We cook by ourselves, this is already a good thing. We like to eat at lot of red meat but we always combine it with vegetables.
E: Only if the results are bad. Let’s see.
G: If everything is normal, we will probably not change your lifestyle.
E: We hope it will help people to be more conscious about their health status, their lifestyle and other related factors. People could for example become aware that living close to a highway or a busy road exposes you to air pollution and affects your health.
ORISCAV-LUX2 was initiated in January 2016 and will run until December 2017. The first wave of ORISCAV-LUX conducted between 2007 and 2008 with more than 1400 participants. The study is a collaborative work led by LIH’s Department of Population Health (Epidemiology and Public Health Research Unit and Clinical and Epidemiological Investigation Centre; project leader: Dr Ala’a Alkerwi) and involving IBBL - Integrated BioBank of Luxembourg, Centre Hospitalier de Luxembourg, University of Liège, Ligue Médico-Sociale, Laboratoires Ketterthill and BioLogistic SAS. The project represents a unique opportunity to collect reliable public health data and increase health awareness among the national population.
More information can be found on the ORISCAV-LUX website: http://www.oriscav.lih.lu
If you are interested in participating, please contact Mrs Cathy Fousse: email@example.com, +352 26970-747.
Photo 1: Exercices on a step are part of the ORISCAV-LUX2 study
Photo 2: Participants can choose to wear an accelerometer around their wrist for one week for the monitoring physical activity
Photo 3: LIH welcomed the 1000th and 1001st ORISCAV-LUX2 participants on 17th August 2017. From left to right: Daniela Valoura Esteves (research nurse), Marylène d’Incau (research nurse coordinator of ORISCAV-LUX2), Elizabeth (ORISCAV-LUX2 participant #1000), Gustavo (ORISCAV-LUX2 participant #1001), Aurélie Wiederkehr (research nurse) and Dr Ala’a Alkerwi (project leader of ORISCAV-LUX2 and Principal Investigator)
Healthcare professionals who wish to be part of a unique network, providing access to up-to-date, accurate and validated information about clinical research.
Investigators and study staff who wish to be part of a unique network, in order to stay abreast of clinical trials taking place in Luxembourg and who are willing to further develop their competencies.